<ѻý>Mahvash Disease Case Resolved With Liver Transplantationѻý> Rare disease should be part of the differential in the presence of massive pancreaticomegaly Nov 22, 2023
<ѻý>PPAR Agonist Led to 'Clinically Meaningful' Improvement in PBC-Related Pruritusѻý> Seladelpar also improved markers of disease activity versus placebo Nov 15, 2023
<ѻý>Novel MASH Drug Reduces Liver Fat in Mid-Stage Trialѻý> At highest dose, thyroid hormone receptor-beta agonist decreased liver fat content by 45% Nov 15, 2023
<ѻý>Emergency Liver Transplant Effective for Severe Acute-on-Chronic Liver Failureѻý> 1-year survival reached 78% for patients who received an emergency transplant Nov 14, 2023
<ѻý>Novel Drug Makes Its Case for Pretreated Primary Biliary Cholangitisѻý> In randomized trial, oral elafibranor induced biochemical response at 1 year in 51% of patients Nov 14, 2023
<ѻý>AKI Response Tied to Improved Survival for Patients Waiting on Liver Transplantѻý> Results highlight the importance of prompt recognition and treatment of acute kidney injury Nov 13, 2023
<ѻý>MASLD Predicted to Increase by 23% by Middle of the Centuryѻý> AASLD president: "No way we are going to be able to transplant our way out of this" Nov 12, 2023
<ѻý>Diet and Liver Health; Gut Microbiome and Cardiometabolic Diseaseѻý> Also in TTHealthWatch: COVID hospitalization data Oct 14, 2023 podcast
<ѻý>Cancer Risk in NAFLD Higher With Early Disease Onsetѻý> 52% greater risk of malignancy for patients diagnosed with fatty liver disease before age 45 Sep 27, 2023
<ѻý>Gene Therapy Promising for Rare Jaundice Syndromeѻý> Early-phase data suggest a dose that can keep bilirubin in check without hours of phototherapy Aug 16, 2023
<ѻý>FDA OKs First Liver-Directed Treatment for Metastatic Uveal Melanomaѻý> Hepzato Kit melphalan delivery system produced objective responses in 36% of patients Aug 15, 2023
<ѻý>Aspartame Is a 'Possible' Carcinogen, WHO Declaresѻý> But the organization's recommended limits on aspartame consumption remain unchanged Jul 13, 2023
<ѻý>NAFLD and T2DM Bodes Higher Risk of Liver Decompensation, Cancerѻý> Several-fold higher risks compared with NAFLD patients without diabetes Jul 11, 2023
<ѻý>'Jarringly' Low Hep C Cure Rates a Decade After New Treatments, CDC Saysѻý> Lack of rapid testing and payer restrictions are creating barriers, experts say Jun 29, 2023
<ѻý>Novel Triple Agonist Nabs Biggest Weight Loss Yet in Obesity Trialѻý> Plus, two other studies on retatrutide show benefit in type 2 diabetes, fatty liver disease Jun 26, 2023
<ѻý>Can AI Help Determine If Liver Cancer Will Respond to Standard Treatment?ѻý> Early model suggests a way to predict progression-free survival Jun 26, 2023
<ѻý>Fecal Matter Transplant Shows Promise in Cirrhosisѻý> Pilot trial demonstrates that FMT can boost gut health, prevent serious infections Jun 25, 2023
<ѻý>'Game Changer' in NASH: Resmetirom Hits Endpoints in Pivotal Studyѻý> Investigational drug more likely to resolve severe form of fatty liver disease, improve fibrosis Jun 22, 2023
<ѻý>Ocaliva for NASH Gets Thumbs Down From FDA Advisorsѻý> Difficulty of risk mitigation for potential drug-induced liver injury weighed heavily on members May 19, 2023
<ѻý>NASH Drug Candidate Comes With 'Serious Risks,' Says FDA Staffѻý> Agency reviewers signal little support for first potential nonalcoholic steatohepatitis drug May 17, 2023
<ѻý>Statins Linked to Slower Liver Disease Progressionѻý> Risk 40% lower with use among those with preexisting liver disease, study found May 04, 2023
<ѻý>Bariatric-Metabolic Surgery More Effective Than Lifestyle Change for NASHѻý> Roux-en-Y bypass or sleeve gastrectomy resolved NASH without exacerbating liver fibrosis Apr 26, 2023
<ѻý>Transplant Chief Was an Organ Recipient Herselfѻý> Years ago, she had a liver transplant. Now she leads Hopkins' pediatric liver transplant program Apr 19, 2023
<ѻý>NKF Roundup: Latest Data on Tolvaptan, Terlipressin, and Lumasiranѻý> More research from the National Kidney Foundation Spring Clinical Meeting Apr 17, 2023
<ѻý>Adjuvant Combo May Change Practice in High-Risk Liver Cancerѻý> Atezolizumab-bevacizumab reduced the risk of recurrence by about 30% Apr 17, 2023
<ѻý>Another Measure of Terlipressin Success in Hepatorenal Syndromeѻý> Goal of 30% reduction in serum creatinine in the absence of full response or HRS reversal Apr 13, 2023
<ѻý>Smaller Liver Transplant Candidates Wait Longer, Less Likely to Receive Organѻý> Disparity mostly affects women, but allocating more livers from smaller donors may help Mar 29, 2023
<ѻý>FDA Mandate on Acetaminophen-Opioid Combinations Appeared Effectiveѻý> Hospitalizations for liver toxicity declined after FDA limited acetaminophen dose Mar 07, 2023
<ѻý>Avoiding Just This Dietary Trigger Helps Resolve Eosinophilic Esophagitisѻý> Easier alternative to six-food elimination diet shown effective Mar 01, 2023
<ѻý>'More Is Not Better' in Two First-Line Trials for Biliary Tract Cancerѻý> No survival benefit with three-drug chemo regimen or clear PFS gain with anti-PD-L1/bevacizumab Jan 22, 2023
<ѻý>Epstein-Barr Virus Tracking After Liver Transplant May Cut Rare Complicationѻý> Observational study provides suggestive evidence Jan 17, 2023
<ѻý>Direct-Acting Antivirals Linked to Improved Outcomes in Chronic Hepatitis Cѻý> All-cause mortality rate significantly lower in treated versus untreated group Dec 13, 2022
<ѻý>Abstinence Tied to Lower Mortality in Alcoholic Cirrhosis With Portal Hypertensionѻý> Benefit observed even in patients with high-risk portal hypertension Dec 08, 2022
<ѻý>Robotic Surgery Proves Its Mettle for Liver Cancerѻý> Fewer cases of liver failure, similar survival versus open liver resection in matched analysis Nov 23, 2022
<ѻý>Will Fresh Look at Obeticholic Acid Data in NASH Sway FDA?ѻý> Latest REGENERATE analysis comes on heels of REVERSE flop Nov 11, 2022
<ѻý>Steroids and G-CSF Boost 90-Day Survival in Severe Alcoholic Hepatitisѻý> Plus: Normothermic machine perfusion for liver transplants and Noom Weight for NASH Nov 11, 2022
<ѻý>Novel Hepatitis B Drug Hints at Long-Term 'Functional Cure' for Some in Early Trialѻý> With 10% efficacy at 6 months post-treatment, a finite HBV treatment may be on the horizon Nov 10, 2022
<ѻý>Efruxifermin Led to NASH Resolution, Fibrosis Improvement in Mid-Stage Trialѻý> Both 50- and 28-mg doses improved fibrosis vs placebo, without worsening of NASH Nov 10, 2022
<ѻý>Maralixibat Takes Out the Itch of Rare Liver Diseaseѻý> Ileal bile acid transporter inhibitor could become second drug for PFIC Nov 09, 2022
<ѻý>Odevixibat Shows 'Encouraging Results' for Kids With Alagille Syndromeѻý> Significant improvements in itching, bile acid levels for rare, life-threatening liver disorder Nov 09, 2022